Loading

Avelos Therapeutics

June 05, 2024
Company Presentation
Oncology
Company Presentation Theater 1
- Avelos is a cutting-edge science based oncology drug development company, particularly focusing on small molecule drugs for novel targets in the areas of synthetic lethality, DNA damage repair and cell cycle. - The company was founded in Sep. 2021, and is headquartered in Seoul. - The founding members include Young-Whan Park (ex-Merck), Soongyu Choi (ex-Bayer), Kangsik Yun (ex-National Oncoventure), who have strong expertise and networks in new drug discovery and development. - Currently, Avelos has 4 oncology drug programs. AVS1001, the first-in-class DNA damage repair & cell cycle inhibitor program, is in IND enabling stage, the others are in lead optimization stage. - The company closed a $8 million Series A financing in 2022, and Series B financing is ongoing.
Avelos Therapeutics
Company Website: http://www.avelostx.com
Lead Product in Development: - AVS1001 : Oncology, NCE, Cell cycle and DNA Damage Response target (preclinical) - AVS1002 : Oncology, NCE, DNA Damage Response target (Discovery) - AVS1003 : Oncology, NCE, DNA Damage Response target (Discovery) - AVS1004 : Oncology, NCE, DNA Damage Response target (Discovery)
Number Of Unlicensed Products (For Which You Are Seeking Partners): 4 oncology drug products

Company HQ City

Seoul

Company HQ State

Seoul

Company HQ Country

Korea, Republic of

CEO/Top Company Official

- CEO : Dr. Young-Whan Park - CTO : Dr. Soongyu Choi - Head of BD : Mr. Kangsik Yun

Development Phase of Primary Product

Pre-Clinical
Speakers
Young-Whan Park, PhD
CEO
Avelos Therapeutics
Back to Session List

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS